BIOMAT Database Logo BIOMAT Database Logo

Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. 2004

Hans Michael Kvasnicka, and Juergen Thiele, and Peter Staib, and Annette Schmitt-Graeff, and Martin Griesshammer, and Jens Klose, and Knut Engels, and Susanne Kriener
Institute of Pathology and First Clinic of Medicine, University of Cologne, Germany. hm.kvasnicka@uni-koeln.de

The effect of imatinib mesylate (imatinib) therapy on angiogenesis and myelofibrosis was investigated and compared with interferon (IFN) and hydroxyurea (HU) in 98 patients with newly diagnosed Philadelphia chromosome-positive/BCR-ABL(+) (Ph(+)/BCR-ABL(+)) chronic myeloid leukemia in first chronic phase and no other pretreatment. By means of immunostaining (CD34) and morphometry, a relationship between microvessel frequency and fiber density was detectable in initial bone marrow (BM) biopsies and sequential examinations after at least 8 months of therapy. First-line monotherapy with imatinib induced a significant reduction (normalization in comparison with controls) of microvessels and reticulin fibers. In most patients, decrease in BM vascularity was associated with a complete cytogenetic response. A significant anti-angiogenic effect was also observed after HU treatment, contrasting with IFN administration or combination regimens (IFN plus HU). In conclusion, our data support the anti-angiogenic capacity of imatinib by normalization of vascularity. In contrast, hematologic response following IFN treatment is independent from BM angiogenesis.

UI MeSH Term Description Entries
D008833 Microcirculation The circulation of the BLOOD through the MICROVASCULAR NETWORK. Microvascular Blood Flow,Microvascular Circulation,Blood Flow, Microvascular,Circulation, Microvascular,Flow, Microvascular Blood,Microvascular Blood Flows,Microvascular Circulations
D009389 Neovascularization, Pathologic A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions. Angiogenesis, Pathologic,Angiogenesis, Pathological,Neovascularization, Pathological,Pathologic Angiogenesis,Pathologic Neovascularization,Pathological Angiogenesis,Pathological Neovascularization
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D001856 Bone Marrow Examination Removal of bone marrow and evaluation of its histologic picture. Examination, Bone Marrow,Bone Marrow Examinations,Examinations, Bone Marrow
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Hans Michael Kvasnicka, and Juergen Thiele, and Peter Staib, and Annette Schmitt-Graeff, and Martin Griesshammer, and Jens Klose, and Knut Engels, and Susanne Kriener
Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
June 2003, American journal of clinical pathology,
Hans Michael Kvasnicka, and Juergen Thiele, and Peter Staib, and Annette Schmitt-Graeff, and Martin Griesshammer, and Jens Klose, and Knut Engels, and Susanne Kriener
[Chronic myeloid leukemia and imatinib mesylate therapy].
January 2004, Vnitrni lekarstvi,
Hans Michael Kvasnicka, and Juergen Thiele, and Peter Staib, and Annette Schmitt-Graeff, and Martin Griesshammer, and Jens Klose, and Knut Engels, and Susanne Kriener
Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine therapy.
May 2005, Haematologica,
Hans Michael Kvasnicka, and Juergen Thiele, and Peter Staib, and Annette Schmitt-Graeff, and Martin Griesshammer, and Jens Klose, and Knut Engels, and Susanne Kriener
Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
September 2004, Haematologica,
Hans Michael Kvasnicka, and Juergen Thiele, and Peter Staib, and Annette Schmitt-Graeff, and Martin Griesshammer, and Jens Klose, and Knut Engels, and Susanne Kriener
Imatinib mesylate in chronic myeloid leukemia.
September 2007, Current stem cell research & therapy,
Hans Michael Kvasnicka, and Juergen Thiele, and Peter Staib, and Annette Schmitt-Graeff, and Martin Griesshammer, and Jens Klose, and Knut Engels, and Susanne Kriener
Bone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate.
January 2008, Indian journal of cancer,
Hans Michael Kvasnicka, and Juergen Thiele, and Peter Staib, and Annette Schmitt-Graeff, and Martin Griesshammer, and Jens Klose, and Knut Engels, and Susanne Kriener
Effect of Imatinib on Bone Marrow Morphology and Angiogenesis in Chronic Myeloid Leukemia.
January 2019, Advances in hematology,
Hans Michael Kvasnicka, and Juergen Thiele, and Peter Staib, and Annette Schmitt-Graeff, and Martin Griesshammer, and Jens Klose, and Knut Engels, and Susanne Kriener
Reduced dose imatinib mesylate therapy for chronic myeloid leukemia.
November 2004, Leukemia & lymphoma,
Hans Michael Kvasnicka, and Juergen Thiele, and Peter Staib, and Annette Schmitt-Graeff, and Martin Griesshammer, and Jens Klose, and Knut Engels, and Susanne Kriener
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
July 2004, Cancer,
Hans Michael Kvasnicka, and Juergen Thiele, and Peter Staib, and Annette Schmitt-Graeff, and Martin Griesshammer, and Jens Klose, and Knut Engels, and Susanne Kriener
Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: rapid response to imatinib mesylate (STI571).
August 2003, Medical and pediatric oncology,
Copied contents to your clipboard!